In May 2026, the team led by Professor Han Jianfeng and Professor Yu Jia from the Department of Neurology at the First Affiliated Hospital (FAH) of Xi’an Jiaotong University (XJTU) successfully performed surgery on a patient with an intracranial aneurysm using the new Pipeline™ Vantage flow diverter for the first time. This marked the first clinical application of Pipeline™ Vantage in Northwest China, demonstrating that the neurointerventional team of the FAH Department of Neurology ranks among the national leaders and remains at the forefront in Northwest China in the field of endovascular treatment for intracranial aneurysms. The patient, a 63-year-old man, was admitted to the Department of Neurology at the FAH after an examination at another hospital for dizziness suggested a suspected aneurysm at the distal M1 segment of the right middle cerebral artery. After admission, the patient underwent comprehensive preoperative examinations, and surgical contraindications were excluded. Cerebral angiography confirmed an irregular, flat, oval aneurysm at the bifurcation of the right middle cerebral artery, with an aneurysm height of 2.4 mm, a maximum width of 6.3 mm, and a neck width of 5.3 mm. After comprehensive evaluation, endovascular treatment was recommended, and the patient and his family agreed to proceed. The team led by Professor Han Jianfeng and Professor Yu Jia performed Pipeline™ Vantage flow diverter implantation under general anesthesia, and the procedure was completed successfully. After surgery, the patient was transferred to the Neurology Intensive Care Unit for observation, returned to the general ward the following day, and has since recovered and been discharged.

The new Pipeline™ Vantage flow diverter offers three major advantages. First, it adopts exclusive surface modification technology, which can reduce thrombogenic activity, protect branch vessels, avoid irritation to the aneurysm wall, and provide greater safety. Second, it is compatible with a 0.021-inch low-profile microcatheter, offering strong vascular access capability, better adaptability to tortuous vessels, and reduced vascular injury. Third, it uses DFT drawn filled tubing technology. With its cobalt-chromium-nickel material, the device provides excellent radial support and radiopacity, making the stent stable and easy to operate, while allowing smoother delivery, retrieval, and distal-end deployment.